×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PRLD – prelude therapeutics incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PRLD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
12:29 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
12/11
07:40 am
prld
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]
12/11
07:30 am
prld
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Medium
Report
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
11/27
07:41 am
prld
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
Low
Report
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
11/27
07:30 am
prld
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Low
Report
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
11/11
11:49 am
prld
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
Low
Report
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
11/8
12:31 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/6
04:22 pm
prld
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
12/11
12:29 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
Report
-1.0%
12/11
12:29 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
Report
-1.0%
Date
Time
Symbol
Headline
Impact
12/20
07:36 am
prld
Form 4 Prelude Therapeutics For: Dec 19 Filed by: Lim Bryant David
High
Report
Form 4 Prelude Therapeutics For: Dec 19 Filed by: Lim Bryant David
12/20
07:34 am
prld
Form 4 Prelude Therapeutics For: Dec 18 Filed by: Vaddi Krishna
High
Report
Form 4 Prelude Therapeutics For: Dec 18 Filed by: Vaddi Krishna
12/11
07:45 am
prld
Form 8-K Prelude Therapeutics For: Dec 11
Low
Report
Form 8-K Prelude Therapeutics For: Dec 11
11/6
04:28 pm
prld
Form 10-Q Prelude Therapeutics For: Sep 30
Medium
Report
Form 10-Q Prelude Therapeutics For: Sep 30
11/6
04:17 pm
prld
Form 8-K Prelude Therapeutics For: Nov 06
Medium
Report
Form 8-K Prelude Therapeutics For: Nov 06
10/24
07:41 am
prld
Form 8-K Prelude Therapeutics For: Oct 24
Medium
Report
Form 8-K Prelude Therapeutics For: Oct 24
10/7
04:11 pm
prld
Form 4 Prelude Therapeutics For: Oct 04 Filed by: Huang Jane
Medium
Report
Form 4 Prelude Therapeutics For: Oct 04 Filed by: Huang Jane
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: